New technologies delivered to your inbox Subscribe
2001-023 – A novel expression system has been developed that selectively expresses ABeta40 or ABeta42 in the secretory pathway. This system enables expression of high levels of specific ABeta peptides. Such a system may be invaluable in developing animal models that critically determine the pathogenicity of individual ABeta peptides. In addition, the system may have general utility as a means of... Read More
2001-021 – Monoclonal antibodies developed against specific portion of the huma sodium iodide symporter (hNIS). Antibody 2-2 and 14f were developed against synthetic peptides representing the 2nd and 14th extramembranous loops of hNIS and antibody FP5a was developed against an MBP-hNIS fusion protein including a carboxyl terminal sequence of hNIS. The antibodies have been characterized and were found... Read More
2001-013 – A non-iterative motion correction that does not use any navigators is described. It can be used with any 3D application and spirals.
2001-009 – SULT2A1 catalyzes the transfer of inorganic sulfate to hydroxysteroids and uses PAPS as the sulfate donor. Genetically based variations in SULT2A1 may affect the metabolism of steroid compounds (DHEA, ethinyl estradiol, minoxidil, androsterone, androstenediol, epiandrosterone, androgens, estrogens, testosterone, and pregnenolone) that are used for drugs, as well as structurally related... Read More
2001-001 – Nearly all elderly persons develop pathologic areas of cell loss and demyelination (called leukoaraiosis), in the central areas of the brain. We have developed an accurate and highly reproducible method for quantitatively measuring the volume of leukoaraiosis from a magnetic resonance image of the brain.
2000-176 – Polyclonal antibodies, NR1, NR2 and NR3 against human and rat PMCa isoforms 1, 2 and 3.
2000-155 – Prosthesis with varying stem stiffness from proximal to distal ends; minimizes stress shielding; decreases bone re-sorption adjacent to proximal end of stem.
2000-131 – An interactive software interface to a detailed brain atlas developed by Kent Ridge Digital Laboratories in Singapore which permits access, display and manipulation of the atlas within the analyze software system. The interface permits rapid and accurate registration of the brain atlas to MRI scans of the brain for the purpose of labeling, segmentation or other functions where defined and... Read More
2000-100 – PAPSS2 is an enzyme that synthesizes PAPS; the high-energy sulfate donor molecule involved in the sulfate conjugation (metabolism) of thousands of drugs, hormones (estrogen), neurotransmitters (dopamine) and many other macromolecules. Rare inactivating mutations in orthologous PAPSS2 genes have been identified as the genetic causes for human spondyloepimetaphyseal dysplasia and murine... Read More
2000-089 – Analytical/software method to quantitate beat-to-beat non-alternating, chaotic variability in electrical repolarization of the heart. This index (TWLI) indicates the presence of a highly malignant arrhythogenic substrate and may be useful for the identification and primary prevention of sudden cardiac death.
2000-080 – The treatment of neutrophil-associated pulmonary inflammation including chronic obstructive pulmonary disease (smoker’s bronchitis), chronic bronchitis, cystic fibrosis, alphal-antitrypsin deficiency, adult respiratory distress syndrome and idiopathic pulmonary fibrosis by lidocaine inhalation.
2000-066 – We have created two lines of transgenic mice expressing human tau with the P301L mutation. Mice expressing the 2-3-10+ human isoform with the P301L mutation develop tau neurofibrillary tangles, motor deficits, and behavioral abnormalities. Mice expressing the longest human tau isofrom (2+3+10+) with the P301L mutation develop balloned neurons as well as neurofibrillary tangles. Motor and... Read More
2000-065 – Mouse class II-deficient HLA-DQB10302, DQA10301 (DQ8) transgenic mice are susceptible to severe collagen-induced arthritis (CIA), an animal model for rheumatoid arthritis. To examine whether polymorphism at the DRB1 locus can modulate DQ-restricted arthritis, we generated double- transgenic (DR/DQ) mice. DRB1*0301 (DR3) was introduced into CIA susceptible DQ8.Abeta transgenic mice to generate... Read More
2000-064 – We developed an HLA-DR3.Abo mouse by introducing the DR3 transgene into a H2Abo mouse, class II negative strain, by mating with BIO.M-DRB1*0301 mice. Experimental autoimmune thyroiditis (EAT) is induced in these mice when immunized with either MTg or HTg.
2000-037 – A 3D motion adjustment pulse sequence is interleaved with magnetic resonance image (MRI) acquisition. This motion adjustment pulse sequence encodes all six degrees of rigid body motion in a single 3D spherical k-space dataset and is used to measure patient motion during the scan. The MRI system’s scan parameters are prospectively adjusted during the scan to offset the effects of patient... Read More
2000-031 – Human SULT1C1 has been shown to metabolically activate planar phenols and the chemical procarcinogen N-OH-2-acetylaminoflurorene. Therefore, genetically based variations in the activity of this enzyme may affect the activation of procarcinogens. In addition, SULT1C1 polymorphisms may play a role in thyroid hormone inactivation since this enzyme metabolizes thyroid hormones. Therefore,... Read More
2000-025 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2000-013 – The development of a delivery mechanism (pill or capsule) for barium sulfate which is used for the purpose of altering the density of stool sufficiently that it can be electronically subtracted. A new software tool (computer algorithm) for electronic subtraction of contrast-laden stool has been developed.
1999-095 – This invention will help allow very high field strength MRI systems to be used safely and effectively as clinical systems for routine patient use.
1999-065 – Investigators are combining mEPO and together with mEPO deficient gene knock-out animals to create a battery of monoclonal antibodies against this eosinophil granular ribonuclease. Highly specific, sensitive antibodies will be produced that will be useful in assays and drug discovery programs for eosinophil-related diseases such as asthma, allergy and inflammation.
1999-064 – Investigators have developed a rabbit polyclonal antisera reactive against murine major basic protein-1 (native protein purified from isolated mouse eosinophils). MBP is a known factor in the asthma, inflammation and allergy pathways. This antibody is highly specific and would be useful in a variety of assays where high specificity and sensitivity are desired.
1999-061 – This is a cell therapy delivery system which allows efficient and long term vascular delivery.
Self-Terminating High-Speed Low-Power Logic Transceiver Enabling Compatibility Between CMOS Based Logic Devices of Differing Supply Voltages
1999-056 – A CMOS based digital output buffer circuit and input buffer circuit, with both circuits forming a transceiver pair, is described. The transceiver enables high speed point-to-point digital communication and hence cannot be used for multi-drop digital buses. The transceiver offers many of the features desired of transceivers. These features include: a) Compliance between transmitting devices... Read More
1999-036 – AVWPC is a comprehensive set of imaging functions which facilitates full exploration and analysis of multidimensional, multimodality biomedical image data sets that runs on PCs using C compilers and operating systems such as Windows. The software also facilitates the development and implementation of advanced imaging algorithms and techniques and easy integration of these into specific... Read More
1999-033 – These methods reduce the audible sound produced by ultrasound scanners in patients. Reduction of fetal stress during ultrasound examination.
1999-003 – Polyclonal antibody and purification thereof that recognizes the Amyloid B. peptide (AB).
1998-097 – A method is described that allows both highly sensitive screening for arterial disease in conjuction with highly specific diagnoses on an MR System with high-speed gradients.
1998-076 – Short term paralysis of underlying musculature to improve cutaneous wound healing in tramatic and non-tramatic wounds.
1998-071 – Substrates for SULT1A1 are; 4-nitrophenol, 17beta-estradiol (E2), diethylstilboestrol (DES), 1-naphol, 4-hydroxytamoxifen, minoxidil, estrone (E1), epinephrine, dopamine, acetaminophen, genistein, other monocyclic phenols. The gene is ubiquitously expressed but especially prominent in liver but also lung, brain, platelet, prostate, placenta, and adrenal gland. Diseases associated with... Read More
1998-066 – The Mayo Clinic is developing and testing a synbiotic (composition of synergistic probiotic organisms and a prebiotic) for clinical indications (Croh'n’s, IBD, immunocompromised patients, patients undrgoing chemo or radiation therapy, patients infected with antibiotic resistant organisms. THe synbiotic has proven to be very effective in several animal trials including animals that were... Read More
1998-060 – A stent that fractures at strategic points to relieve arterial stress after placement.
1998-036 – Histamine N-methyltransferase (HNMT, EC184.108.40.206) catalyzes a major pathway in the metabolism of histamine. The only pathway for the termination of the neurotransmitter actions of histamine in the human CNS is N-methylation catalyzed by HNMT, and approximately 70% of histamine in bronchial epithelium is metabolized by HNMT. Mayo investigators have cloned the cDNA and gene for HNMT in humans and... Read More
1998-026 – Mutations in the tau gene have been discovered that are linked to Tau pathologies. Identification of these mutations can lead to animal models of neurodegenerative diseases to be developed and provides methods for determining a diagnosis of neurodegenerative disease in a patient.
1998-009 – Multiple myeloma is a universally fatal plasmaproliferative disorder despite aggressive chemotherapy and transplantation. An immunotherapeutic approach to target myeloma cells for killing by toxin genes or radioisotopes may be very useful therapeutically in myeloma and such approaches have already been shown to have clinical activity in other malignancies. Our investigators have devised a... Read More
1997-112 – An inbred strain of transgenic mice that show tissue-specific expression of the human MUC1 gene. These animals express a form of the human MUC1 gene which codes for the core protein of a mucin expressed by glandular epithelia and carcinomas which develop from these tissues. The core protein is underglycosylated in these cancers and therefore represents a possible target for immunotherapy.... Read More
1997-109 – System for clinical image display.
1997-106 – Mayo researchers have established several human multiple myeloma cell lines, including the ANBL-6, KP-6, KAS-6/1 and DP-6 lines.
1997-103 – Expanding screw with increased strength of bone-screw interface for spinal internal fixation surgeries.
1997-071 – We generated an HLA-DR4ß(NT) transgene construct in which positions 110 and 139 were altered to resemble endogenous mouse H2 Aß molecules. This construct was introduced into (B10 x SWR) embryos, and DR4ß(NT) transgenic mice were produced. The transgene was transferred into B10.RFB3 (Eß0 Ealphap) mice. The transgene-encoded DR4ß molecules paired with endogenous Ealpha chains to form stable... Read More
1997-069 – We developed an HLA-DR2 mouse model by introducing a human DRB1*1502(DR2DW12) transgene into CIA susceptible BIO.RQB3 (H2A8) mice. These mice showed a significant reduction in the incidence and severity of arthritis. For further information please see Human Immunology, 1996, 50:54-60.
1997-035 – This technology is a T-cell line that lacks the protein tyrosine kinase, ZAP-70. ZAP-70 plays a critical role in the initiation of lymphocyte activation responses to antigenic stimuli. The cell line can be used to define the mechanisms of ZAP-70 activation and function in T-cell signaling. This line can be used also to confirm the mechanism of action of ZAP-70 targeted drugs. This is the... Read More
1997-014 – A novel, topical chemotherapeutic drug in vanishing cream to treat malignancy.
1997-001 – With the aging of the population, osteoporosis is emerging as a major public health problem. Drugs used to treat osteoporosis can be classified into those that decrease bone resorption and those that increase bone formation. While a number of anti-resorptive therapies for osteoporosis are presently available, there is a clear need for novel anabolic approaches. New insights gained from a... Read More
1996-112 – Enable clinicians to selectively cool the brain, independent of core temperature, as a means of cerebral protective therapies.
1996-106 – Mayo has issued patent claims for inhibiting hydroxymethylglutaryl coA reductase activity to slow heart valve degeneration.
1996-100 – Radiation force of arbitrary frequency is generated on the object using a single ultrasound beam. This system is used for information transmission, object detection or imaging. 3D blood flow vector imaging and imaging of internal structures of living cells.
1996-076 – Transgenic mouse (Tg2576) carrying the Swedish mutation for Alzheimer’s Disease. This mouse was developed by Dr. Karen Hsiao Ashe at the University of Minnesota and is exclusively licensed to Mayo. This mouse develops age-related neuropathology, including development of amyloid plaques and behavioral changes, and can be used in research related to Alzheimer’s Disease and other... Read More
1995-155 – HFOBER cells are hFOBs stably transfected with human estrogen receptor; subclones HFOB/ER-3 and HFOB/ER-4 express levels of estrogen receptor consistent with the range of levels measured in human osteoblasts. The HFOBER cell lines have a complete concatenation of transcription factors such that the estrogen receptor is transactionally active; estrogen-regulated functions are maintained. The... Read More
1995-140 – Transgenic mouse models for asthma were developed that express interleukin-5 under the control of a lung epithelial specific promoter. All mice express abnormally high levels of eosinophils in those regions and display symptoms consistent with the underlying physiologic conditions. The CCIL-5 mouse line is a superb animal model for the study of asthma. The animals show hyperactivity to... Read More
1995-139 – Transgenic mouse models for eosinophil-mediated tissue inflammation were developed that express interleukin-5 under the control of a T-cell specific promoter. All mice express abnormally high levels of eosinophils in those regions and display symptoms consistent with the underlying physiologic conditions. The NJ1638 mice are models for hypereosinophilic syndromes and have high levels of... Read More